Journal of Research in Pharmacy Practice
Volume:5 Issue: 2, AprJun 2016

Pyelonephritis is an inflammatory process, and oxidative stress plays a major role in it. Anti‑inflammatory or antioxidant therapy given concomitantly with antibiotics should lower the risk of postpyelonephritic scarring. As the lack of review studies in the use of antioxidants in urinary tract infections was detected, this study was designed. We conducted a review of available articles in PubMed and Google Scholar with a simple review, using keywords of “antioxidant” and “pyelonephritis” with all their possible synonyms and combinations. Only interventional studies were collected. There were neither limitations on time, nor the location of the study, type of subjects, administration rout of the antioxidant drug, and the antioxidant drug used. After studying the abstracts or in some cases the full text of articles, they were categorized based on the type of antioxidant, type and number of subjects, rout of administration, dosing, duration of treatment, year of publication of the paper, and the results. Atotal of 66 articles published from 1991 to 2015 were found by studying just the title of the papers. Studying the abstracts reduced this number to 51 studies. Antioxidants used for this condition were Vitamins A, E, and C, cytoflavin, caffeic acid phenethyl ester, ebselen, allopurinol, melatonin, N‑acetylcysteine, oleuropein, montelukast, oxytocin, ozon, dapsone, pentoxifyllin, tadalafil, bilirubin, cranberry, meloxicam, L‑carnitine, colchicine, perfluoran, methylprednisolone, and dexamethasone. Studies show that antioxidants are capable of reducing oxidative stress and can be used effectively along with antibiotics to reduce the scar formation.

Periodontitis is known to have multifactorial etiology, involving interplay between environmental, host and microbial factors. The current treatment approaches are aimed at reducing the pathogenic microorganisms. Administration of beneficial bacteria (probiotics) has emerged as a promising concept in the prevention and treatment of periodontitis. Thus, the aim of the present study is to evaluate the efficacy of the local use of probiotics as an adjunct to scaling and root planing (SRP) in the treatment of patients with chronic periodontitis and halitosis.

This is a randomized, placebo‑controlled, double‑blinded trial involving 32 systemically healthy chronic periodontitis patients. After SRP, the subjects were randomly assigned into the test and control groups. Test group (SRP + probiotics) received subgingival delivery of probiotics and probiotic mouthwash, and control group (SRP + placebo) received subgingival delivery of placebo and placebo mouthwash for 15 days. Plaque index (PI), modified gingival index (MGI), and bleeding index (BI) were assessed at baseline, 1 and 3 months thereafter, whereas probing depth (PD) and clinical attachment level were assessed at baseline and after 3 months. Microbial assessment using N‑benzoyl‑DL‑arginine‑naphthylamide (BANA) and halitosis assessment using organoleptic scores (ORG) was done at baseline, 1 and 3 months.

All the clinical and microbiological parameters were significantly reduced in both groups at the end of the study. Inter‑group comparison of PD reduction (PDR) and clinical attachment gain (CAG) revealed no statistical significance except for PDR in moderate pockets for the test group. Test group has shown statistically significant improvement in PI, MGI, and BI at 3 months compared to control group. Inter‑group comparison revealed a significant reduction in BANA in test group at 1 month. ORG were significantly reduced in test group when compared to control group.

Within the limitations of the study, the present investigation showed that the adjunctive use of probiotics offers clinical benefit in terms of pocket depth reduction in moderate pockets and reduced oral malodor parameters.

Effects of ascorbic acid on hemodynamic parameters of septic shock were evaluated in nonsurgical critically ill patients in limited previous studies. In this study, the effect of high‑dose ascorbic acid on vasopressor drug requirement was evaluated in surgical critically ill patients with septic shock.

Patients with septic shock who required a vasopressor drug to maintain mean arterial pressure >65 mmHg were assigned to receive either 25 mg/kg intravenous ascorbic acid every 6 h or matching placebo for 72 h. Vasopressor dose and duration were considered as the primary outcomes. Duration of Intensive Care Unit (ICU) stay and 28‑day mortality has been defined as secondary outcomes.

During the study period, 28patients(14 in each group) completed the trial. Mean dose of norepinephrine during the study period (7.44 ± 3.65 vs. 13.79 ± 6.48 mcg/min, P=0.004) and duration of norepinephrine administration(49.64±25.67vs. 71.57±1.60h, P = 0.007) were significantly lower in the ascorbic acid than the placebo group. No statistically significant difference was detected between the groups regarding the length of ICU stay. However, 28‑day mortality was significantly lower in the ascorbic acid than the placebo group (14.28% vs. 64.28%, respectively; P = 0.009).

High‑dose ascorbic acid may be considered as an effective and safe adjuvant therapy in surgical critically ill patients with septic shock. The most effective dose of ascorbic acid and the best time for its administration should be determined in future studies.

Patients on hemodialysis (HD) have a high risk for cardiovascular morbidity and mortality. Cardiac troponins are biomarkers for diagnosing acute myocardial injury or infarction. There is considerable controversy that exists in the frequency and significance of cardiac troponins in predicting cardiac injury and ischemia in HD patients.

In this cross‑sectional study, all HD patients more than 18‑year‑old, who were at least 3 months under HD, and had no sign and symptom of active cardiovascular disease (CVD), in two HD centers were enrolled. One hundred and one patients fulfilled the inclusion criteria. Blood sample for cardiac troponin I (cTnI) was drown before the initiation of HD session during their routine monthly blood testing from patients’ vascular access arterial line. cTnI levels were measured by a high‑sensitivity assay, VIDAS troponin I Ultra kit, and correlated with patients’ demographic, clinical, and laboratory results.

The patients’ different demographic and clinical characteristics had no statistically significant correlation with troponin levels except for marginal trend for past medical history of diabetes and hyperlipidemia with corresponding P values of 0.072 and 0.055. Twenty‑six patients had cTnI level more than 0.01 µg/L and only two patients had cTnI level more than 0.11 µg/L. For laboratory results, only fasting blood sugar had statistically significant correlation with patients’ cTnI level(r = 0.357, P = 0.0001).

Frequency of significant elevation of cTnI level in our asymptomatic HD patients was very low and if such elevation is found in this population, it may be considered as a sign of active CVD.

To develop a valid and reliable instrument in the Persian language for evaluating patient satisfaction with services provided in community pharmacies.

We selected a valid and reliable instrument from the literature and translated it to the Persian language. Some new items were added to the first draft based on the special characteristics of the Iranian health system. Then, the feasibility of utilizing the new instrument was assessed. In the third step, we conducted a formal content validity study to calculate content validity indices. Having completed the content validity study, the factorial structure of new instruments was determined by implementing a factorial analysis. Finally, the reliability of the instrument was assessed by assessment of Cronbach’s alpha coefficient and test‑retest reliability.

The developed instrument demonstrated suitable validity and reliability. The final instrument showed desirable content validity, with inter‑rater agreement of 94% and 97% for relevance and clarity, respectively. Scale content validity indices for relevance and clarity were calculated as 96% and 92%, respectively, and comprehensiveness was calculated as 100%. Factor analysis resulted in seven factors with a cumulative variance of 62.14%. In internal consistency reliability, Cronbach’s alpha for the whole instrument was 0.912. About test‑retest reliability, six items showed “almost perfect” agreement, 18 items showed “substantial” agreement, and three items showed “moderate” agreement. Therefore, test‑retest reliability assessment too demonstrated appropriate results.

The instrument demonstrated excellent validity and reliability for application in Iran. This instrument is useful for evaluating patient satisfaction with services provided in community pharmacies in the Persian‑speaking communities.

The principal aim of this study was to explore the self‑perception of community pharmacists of their professional identity and roles and how they think patients and doctors perceive them. The study also aimed at exploring their opinions regarding role expansion and how they assess their capabilities.

This is an exploratory study that employed qualitative method. Individual, in‑depth interviews were conducted with a purposive sample of 50 community pharmacists working in Khartoum State, Sudan, from October to November 2015. Each interview was recorded, transcribed, and coded into themes. Thematic analysis was carried out.

The study revealed nine different identities of community pharmacists including supplier of medicines, medicines maker, dispenser, patient counselor, medicines expert, clinical practitioner, health promoter, monitor of medicines use, and family practice identity. Participants described that most of the patients value their professional role while doctors perceive them as merely dispensers. Most of participants believe that they are capable to fulfill their roles; however, they identified the need for continuous education. The study revealed that community pharmacists are thirst to role expansion.

The study concluded that community pharmacists are aware of the different identities of their profession. The good recognition of their role by patients reflects good service provided while lack of integrated primary health care system that join doctors and pharmacists resulted in lack of pharmacists’ recognition by doctors. Continuous educational program is needed for community pharmacists, and role expansion will allow for better self‑perception and better profession contribution in healthcare.

Self‑medication is common among patients with gastrointestinal (GI) symptoms. This study was performed to evaluate self‑medication among patients who fulfilled irritable bowel syndrome (IBS) and dyspepsia diagnostic criteria and to investigate the appropriateness of self‑medication with chemical and herbal drugs.

Aprospective, descriptive cross‑sectional study was conducted in outpatient’s GI clinics at Shiraz from November 2011 to May 2012. A GI specialist visited the patients and recruited those who had IBS (base on Rome III adapted criteria) or functional dyspepsia. We surveyed self‑medication among these patients, using a questionnaire containing specific questions about self‑medication.

One thousand four hundred and forty‑seven patients visited by the GI specialist during the study period. Seven hundred and forty‑seven patients had the inclusion criteria, 337 of them fulfilled criteria for IBS, with IBS‑mixed (52%) being the most prevalent subtype, and 410 patients had dyspepsia. Overall, 78.8% of the total participants had recently sought medical attention for their GI complaint. Twenty‑eight percent of patients selected inappropriate medication for their GI complaints. The H2‑blockers class were most common medicines reportedly used. We did not find any significant relationship between age, gender, level of education, marital status, and self‑medication frequency.

Patients who fulfilled criteria for IBS had a high tendency to self‑treat their GI symptoms, use of acid‑suppressive agents was common among patients. Around one‑third of patients self‑treated GI symptoms inappropriately. Consequently, the concept of self‑medication among patients has to be revised. We recommend conduction of educational programs to improve self‑medications selection and attitude among patients to reduce the burden on other health care resources.

To monitor pain intensity, pain symptoms, and medication use in elderly with dementia.

Nursing home residents above 65 years of age, diagnosed with dementia, and showing pain symptoms were included in the study. The patients’ mental status was monitored through a mini‑mental state examination score and observations of pain symptoms using Part 1 of the Mobilization‑Observation‑Behaviour‑Intensity‑Dementia‑2 (MOBID‑2) pain scale. Community pharmacists reviewed the patients’ medication use, and the prescriptions were compared with guidelines for treatment of geriatric patients. Alterations to the patients’ medicine use were forwarded to the general practitioners.

Sixty‑one nursing home residents diagnosed with dementia were identified, 15 of these fulfilled the inclusion criteria, and 12 agreed to participate in the study. The mean age was 87 years of age (range: 77–96), and 42% of the residents were males. The patients’ overall pain intensity was 83% for observations on the numeric pain rating scale (NRS) >0 and 67% for NRS ≥3. Most painful were the situations in which the residents were to mobilize their legs, turn around to both sides of the bed, and when sitting on the bed. The medication reviews identified a total of 95 individual prescriptions, and 33% of these were for nervous system medications, followed by medicines for the treatment of alimentary tract and metabolism disorders (31% of total). Eleven prescriptions for pain medicine were identified; the majority of these were for paracetamol and opioids. Seventeen proposals to patients’ medication use were suggested, but the general practitioners accepted only 6% of these.

This study indicates that the MOBID‑2 pain scale in combination with medication reviews can be used as a tool for optimization of patients’ medication use. However, we recommend the conduction of a larger‑scale study in multiple settings, to validate our results and the generalizability of the findings.

Hospitalization and subsequent discharge home often involve discontinuity of care, multiple changes in medication regimens, and inadequate patient education regarding the instruction of drug use, respiratory devices, and disease information and also lack of information about the drug’s side effects that can lead to medication nonadherence and low level of treatment satisfaction. Hence, we decided to design a study to determine the effect of patient counseling at discharge and also their follow‑up by pharmacist on their treatment satisfaction and medication adherence.

A total number of 154 patients within the age of 18–65 years old participated in the study from August 2013 to March 2014. Patients in the intervention group received pharmacist counseling and necessary education about their prescribed medications at discharge. We set up two follow‑up schedules for this group and one for control group, and then we compared the medication adherence and satisfaction in two groups. The primary outcome of this study was a significant increase in adherence to medication regimen and treatment satisfaction of the case group compare to control group after the intervention of pharmacist at the time of discharge.

There were significant differences in medication adherence and satisfaction between the groups at the time of second follow‑up. Medication adherence in the study group is 42.9% more than the control group, also the treatment satisfaction determined to be 33.5% more than patients in control group. Furthermore, we found that, in intervention group, no one is readmitted while among the patients in control group eight people readmitted.

Counseling patients at the time of discharge and regular follow‑up improves patient’s medication adherence and treatment satisfaction and consequently improves clinical outcomes.

In this study, we aimed to evaluate the attachment to stress ulcer prophylaxis (SUP) guideline in the neurology wards of two teaching and nonteaching hospitals.

A total of 243 patients were retrospectively reviewed in the neurology wards of two teaching and nonteaching hospitals. To assess the appropriate administration of SUP, an internal guideline was prepared using the American Society of Health‑System Pharmacists (ASHP) protocol.

SUP prescriptions were noncompliant with ASHP guideline in about 93.1% and 84.6% of cases in the nonteaching and teaching hospitals, respectively.

SUP may be better practiced in teaching hospitals versus nonteaching ones.

Pharmacy‑driven medication history (MH) programs have been shown to reduce the number of serious or potentially life‑threatening (S/PLT) medication discrepancies (MDs) in many settings, but not Intensive Care Units (ICUs).

MHs were repeated over a 6‑week period. Demographics, number, and nature of MDs were documented. Discrepancy severity was graded using a previously published method. Primary outcome was the proportion of MHs containing >1 S/PLT MDs.

Sixty‑three MHs were repeated. Pharmacy MHs were less likely to contain ≥1 S/PLT MDs (0% vs. 50%, P < 0.001).

Pharmacy MHs contained fewer S/PLT MDs in this small sample. S/PLT MDs on admission and home medication lists were common in patients admitted to the medical ICU. Pharmacy‑driven medication reconciliation (MR) reduced the number and frequency of these discrepancies. Further research is required to improve current MR procedures.

Sialadenitis is a rare adverse effect of captopril. We report a case of captopril‑induced sialadenitis in a patient with end‑stage renal disease (ESRD). A 20‑year‑old man with ESRD encountered parotid and submandibular swelling after receiving two doses of captopril, administered sublingually. Despite of prescribing dexamethasone, resuming hemodialysis, and discontinuing other drugs that also can cause parotitis, he improved later than what was reported in patients with normal renal function. In conclusion recovery from captopril‑induced sialadenitis in patients with ESRD may be more prolonged than that of patients with normal renal function; moreover, early hemodialysis which helps in drug removal may be the most effective treatment.